Pfizer Inc. (NYSE:PFE) Shares Sold by JCIC Asset Management Inc.

JCIC Asset Management Inc. lowered its stake in Pfizer Inc. (NYSE:PFE) by 1.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 97,890 shares of the biopharmaceutical company’s stock after selling 1,815 shares during the quarter. Pfizer comprises about 1.4% of JCIC Asset Management Inc.’s portfolio, making the stock its 29th biggest holding. JCIC Asset Management Inc.’s holdings in Pfizer were worth $4,210,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Castle Rock Wealth Management LLC grew its stake in shares of Pfizer by 3.8% in the 2nd quarter. Castle Rock Wealth Management LLC now owns 5,756 shares of the biopharmaceutical company’s stock valued at $277,000 after buying an additional 212 shares in the last quarter. Providence Wealth Advisors LLC grew its stake in shares of Pfizer by 0.6% in the 2nd quarter. Providence Wealth Advisors LLC now owns 40,404 shares of the biopharmaceutical company’s stock valued at $1,597,000 after buying an additional 230 shares in the last quarter. TD Capital Management LLC grew its stake in shares of Pfizer by 12.0% in the 2nd quarter. TD Capital Management LLC now owns 2,183 shares of the biopharmaceutical company’s stock valued at $85,000 after buying an additional 234 shares in the last quarter. Oarsman Capital Inc. grew its stake in shares of Pfizer by 0.9% in the 2nd quarter. Oarsman Capital Inc. now owns 26,320 shares of the biopharmaceutical company’s stock valued at $1,031,000 after buying an additional 234 shares in the last quarter. Finally, Bollard Group LLC grew its stake in shares of Pfizer by 0.3% in the 2nd quarter. Bollard Group LLC now owns 80,350 shares of the biopharmaceutical company’s stock valued at $3,147,000 after buying an additional 237 shares in the last quarter. 64.99% of the stock is owned by institutional investors.

In related news, insider John D. Young sold 150,000 shares of the company’s stock in a transaction on Thursday, November 11th. The stock was sold at an average price of $50.06, for a total value of $7,509,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.05% of the company’s stock.

PFE has been the subject of several recent research reports. Royal Bank of Canada set a $44.00 price target on Pfizer in a research note on Thursday, July 29th. Benchmark upped their target price on Pfizer from $29.00 to $45.00 and gave the stock a “buy” rating in a research report on Friday, November 5th. Morgan Stanley upped their target price on Pfizer from $45.00 to $48.00 and gave the stock an “equal weight” rating in a research report on Tuesday, October 12th. Independent Research raised Pfizer to a “buy” rating and set a $53.00 target price for the company in a research report on Thursday, November 11th. Finally, JPMorgan Chase & Co. set a $42.00 target price on Pfizer in a research report on Friday, November 5th. Eight equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $49.00.

Shares of PFE traded down $0.19 during mid-day trading on Thursday, hitting $50.89. The company’s stock had a trading volume of 18,556,753 shares, compared to its average volume of 30,943,912. Pfizer Inc. has a one year low of $33.36 and a one year high of $52.83. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.12 and a current ratio of 1.37. The firm has a market capitalization of $285.64 billion, a PE ratio of 15.15, a price-to-earnings-growth ratio of 1.16 and a beta of 0.72. The stock’s 50-day moving average is $45.01 and its two-hundred day moving average is $43.27.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, November 2nd. The biopharmaceutical company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.26. The company had revenue of $24.09 billion during the quarter, compared to analysts’ expectations of $22.82 billion. Pfizer had a return on equity of 31.66% and a net margin of 27.66%. Pfizer’s revenue for the quarter was up 134.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.72 earnings per share. Analysts expect that Pfizer Inc. will post 4.2 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Monday, December 6th. Investors of record on Friday, November 5th will be paid a $0.39 dividend. The ex-dividend date is Thursday, November 4th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 3.07%. Pfizer’s payout ratio is 46.43%.

Pfizer Company Profile

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Featured Story: Special Purpose Acquisition Company (SPAC) – What You Need to Know

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.